Compare KRO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | PHAR |
|---|---|---|
| Founded | 1916 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | 409 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.5M | 885.7M |
| IPO Year | 2004 | 2020 |
| Metric | KRO | PHAR |
|---|---|---|
| Price | $6.42 | $13.18 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 258.0K | 14.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $6.75 | $10.04 |
| Revenue Next Year | $8.36 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $9.54 |
| 52 Week High | $7.89 | $21.34 |
| Indicator | KRO | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 40.17 |
| Support Level | $6.08 | $11.84 |
| Resistance Level | $6.71 | $13.61 |
| Average True Range (ATR) | 0.30 | 0.45 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 1.36 | 45.60 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.